Skip to content
Molecules
SEKISUI XenoTech DD Blog Logo

SEKISUI XenoTech Featured on Labiotech.EU

Understand which transporters are involved in a drug’s absorption, distribution & excretion

Originally posted on Labiotech.EU

How can you build the best case for a new drug application to the regulatory agencies? Preclinical studies are a crucial part in determining the pharmacokinetics of a drug – and more specifically how it is going to interact with drug transporters. So reaching out to the leading provider and consultant in this area (with strong academic roots) is the logical step at this stage of development.

Measurement of the potential of new drugs to be substrates or inhibitors of drug transporters is important in evaluating the safety of a drug in the preclinical development process, as well as to predict potential pharmacokinetic based interactions with other medicines.

Transporters have become increasingly important in drug development due to the major role they play in absorption, distribution and excretion of endogenous and exogenous compounds. The FDA & EMA emphasise the importance of evaluating new drug candidates for transporter-mediated drug-drug interactions (DDI) with a determination of substrate and inhibition potential.

Experienced Contract Research Organizations (CRO) are positioned to help ease the process for developers, in order to help get their drug to an FDA standard.

SEKISUI XenoTech is one such contract research company – positioned perfectly with core focus around in vitro preclinical definitive models (GLP / non-GLP). Specifically, they are known as a leader in the field of Drug TransportDrug Metabolism and DDI.

SEKISUI XenoTech performs in vitro transporter studies to determine if compounds are substrates or inhibitors of clinically-relevant transporters using validated and industry accepted test systems.

Access to the most extensive library of transporters & assays in the world makes them an easy choice for biotechnology and pharmaceutical companies worldwide.

The team of professionals and researchers at SEKISUI XenoTech are also publishing novel information on drug transporters…

Continue reading at Labiotech.EU.

Learn more about:

About the Authors

Michael Millhollen received his bachelor's degree in Visual Communications from the University of Kansas and has over 20 years of experience in marketing and communications. As Global Marketing Manager, he is dedicated to the objective of sharing SEKISUI XenoTech’s scientific expertise and knowledge with scientists around the world.

Read more

about our recent drug transporters research

Our drug metabolism experts are commited to quality results for your preclinical success

Learn More

about our drug transporters research services

“Isolation of subcellular fractions: Tissue > Homogenate > S9 > Cytosol > Microsomes